Yale Cancer Center
@YaleCancer
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.
Dr. David Rimm + @YalePathology colleagues have developed Troplex, a test that measures #HER2 & #TROP2 levels in #breastcancer tumors—helping oncologists choose the most effective antibody-drug conjugates. bit.ly/457oUp7 @SmilowCancer @JCOPO_ASCO @YaleMed

Congratulations to Dr. Etienne Leveille @MuschenLab, recipient of a postdoctoral fellowship grant from @lymphoma! ➡️ medicine.yale.edu/news-article/l… @SmilowCancer @YaleMedicine @YNHH @YaleHemOnc

Congratulations to the 7 members of @YaleCancer to receive funding as Colton Center for Autoimmunity awardees: @CraigMCrews, @MarkGerstein, Dr. James Hansen, Dr. Smita Krishnaswamy, @SaltzmanLab, @mdvesely, + Dr. Dianqing (Dan) Wu. ventures.yale.edu/news/yales-col… @SmilowCancer…

A new @Nature study led by Drs. Harriet Kluger + @aaronmring reveals that naturally-occurring autoantibodies can boost or block #immunotherapy effectiveness by up to 10x. This breakthrough may explain why treatments only work for some patients. yalecancercenter.org/news-article/n……

It was such an honor to help tell Anthony's story with help from the amazing 'Medical Stories' team. We hope this docuseries raises awareness about neuroendocrine tumors. Watch on your local @PBS station, YouTube, or the link below.👇🦓
After years of stomach issues, Anthony was diagnosed with Stage 4 Neuroendocrine Tumors #NETs. With expert care from @PamelaKunzMD at @SmilowCancer, he underwent surgery and is now receiving ongoing treatment. Watch: medicalstories.tv/title/nets/ @YaleCancer @YaleMed @YNHH…
RSVP: Community Level #LiverDisease Prevention Participate in a dialogue on community-level prevention of chronic liver disease between @YaleLiverCancer + @CTDPH. 🗓️August 28, 2025 ⌚️11:30am-5:30pm 📍The Anylan Center, New Haven ➡️bit.ly/44OSkHm @SmilowCancer @YaleMed…

Dr. Sylvia Kurz @NeurologyYale joins @DrEricWiner tonight at 7:30pm for a discussion on the evolving field of neuro-oncology, as well as breakthroughs and patient treatment strategies. 🔹Listen live @wnpr 🔹Download @ApplePodcasts 🔹Watch @YouTube @SmilowCancer @YaleMed @YNHH

Congratulations to @ShariBodofsky, @YaleRadOnc resident and accomplished medical illustrator! Her work was selected for the cover of The Red Journal @IJROBP. She also uses her art to help patients understand #radiationtherapy + will present on this at #ASTRO26. @SmilowCancer

🚨Registration is open🚨 Yale Advancements in Oncology: Implementing the Best Science from ASCO® 2025 and Beyond 🗓️Friday, Sept. 26 🕖7:15am-3:30pm 📍New Haven Lawn Club RSVP: bit.ly/40fPHgq @SmilowCancer @YaleMed @YNHH @YaleCME

Congratulations to @BraunMDPhD + @sidichen for being named Clinical Laboratory Integration Program (CLIP) awardees by @CancerResearch! CLIP supports early-phase studies that test the translational potential of new immunotherapy approaches. medicine.yale.edu/news-article/d… @SmilowCancer…

A study of #bloodglucose in women with #breastcancer found levels ⬇️ slightly during chemotherapy vs. baseline. Without proper management, these changes may ⬆️ the risk of morbidity + mortality. clinical-breast-cancer.com/article/S1526-… @SmilowCancer @CBCjournal @maryam_lustberg @YaleBreast
Yale researchers engineered an antibody, #TMAB3, to carry immune-activating RNA directly to hard-to-treat tumors-shrinking tumors, ⬆️ survival, + avoiding healthy tissue. “This lays the foundation for personalized, tumor-targeted RNA therapies,”@Escobar_Lab.…

With @JensaMorrisMD, @DrRoyHerbstYale, and @BillingsleyMd, we are excited to welcome to our new hospitalists joining @SmilowHospSvc! @YaleCancer @YaleMed @YNHH
A new phase 2 study shows coadministering leucovorin with pralatrexate significantly ⬇️ oral mucositis in patients with relapsed/refractory peripheral T-cell #lymphoma and can be considered a prophylactic therapy. sciencedirect.com/science/articl… @SmilowCancer @YaleHematology…

A new study with @BewersdorfJan + @Dr_AmerZeidan shows adding durvalumab to azacitidine did not improve response or survival in older pts with #AML or HR #MDS, even in those with RNA splicing factor mutations. journals.sagepub.com/doi/10.1177/20… @TAHematol @SmilowCancer @YaleHematology
Immune landscape in HIV-associated lung cancers— This issue’s cover features work by @BrindaEmu & team @YaleCancer showing the tumor microenvironment of non-small cell lung cancer impairs immune cell function among people with HIV: jci.org/articles/view/… The image shows…
A new study led by @lisafucito explored oral #nicotine pouches for #smokingcessation + found prelim support for their use as a cigarette substitute. Higher-nicotine pouches may have a stronger impact on smoking behavior. tobaccocontrol.bmj.com/content/early/… @TC_BMJ @SmilowCancer @YalePsych
Addressing obesity can help improve outcomes in #breastcancer. A new study from @maryam_lustberg + @YaleBreast colleagues finds no major safety concerns with #GLP1 meds so far, but more research is needed on safe, effective, long-term weight loss options. onlinelibrary.wiley.com/doi/10.1002/ca……
Look forward to sharing our science led by @Cross_JL & @shawnwahi @YaleMed @YaleCardiology @YaleIMed @YaleCancer @escardio 2025 in Madrid Spain! #AI #LLM #CMR & #ML models to predict ICI cardiotoxicity w/new risk calculator @attilafehermd @ibolya_csecs @mtysar @MariamBaigMD
Results from the AMBER part 2B trial reveal cobolimab + dostarlimab as safe with promising efficacy in advanced/metastatic #NSCLC. Findings support continued investigation in this population. aacrjournals.org/clincancerres/… @SmilowCancer @CCR_AACR @YaleThoracic
